Retrospective clinical studies showed that tissue expression levels of FABP5 are associated with prognosis in HCC patients[96,186,187]; however, no significant differences in serum FABP5 levels were observed between HCC patients and non-cancerous hepatitis patients[188]. This evidence concerns the gene FABP5 and hepatitis A virus infection.